Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost

Anticoagulant Eliquis has taken the U.S. warfarin alternative market by storm, passing up warfarin itself in the process. But partners Bristol-Myers Squibb and Pfizer believe an atrial fibrillation screening push could give the drug another leg up.